Industry News
Biotechnology Industry News
Praxis Precision Medicines…
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a quarter of patients discontinuing the
Biotech backer OrbiMed has raised…
Biotech backer OrbiMed has raised $1.86 billion in commitments for its fifth fund aimed at “growth-oriented healthcare companies.”
Xoma Royalty kicked off the week…
Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical setbacks.
Skin-focused Sirona Biochem is…
Skin-focused Sirona Biochem is liquidating its R&D subsidiary after a pair of financing deals and a licensing agreement with AbbVie’s Allergan Aesthetics fell apart.
A new Caribbean company has…
A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. Excalipoint, incorporated in the Cayman Islands, is paying $10 million upfront to China’s Lepu Biopharma in return for the rights to
A phase 3 trial of Spine…
A phase 3 trial of Spine BioPharma’s chronic low back pain candidate has missed its primary endpoint. But, with the biotech pinning the failure on a “very high sham control response,” management plans to meet
Sanofi is handing over $130…
Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease treatment that is currently being considered for approval by Chinese regulators.
4D Molecular Therapeutics has…
4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.
When you think of biotech hubs,…
When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or the scenic hills of San Francisco’s Bay Area.
Allogene Therapeutics has reported…
Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its key CAR-T cell therapy trial for large B-cell lymphoma (LBCL).
After the surprise departure of…
After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take too long to find a successor. Maziar Mike Doustdar, currently the company’s EVP of international operations,
A PD-L1xVEGF bispecific antibody…
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, instilling hope that the asset can succeed in a newly approved U.S. trial.
AbbVie is ending development of an…
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study failed to demonstrate sufficient efficacy results.
Nuvectis Pharma has dropped plans…
Nuvectis Pharma has dropped plans to develop NXP800 in ovarian cancer after tallying two unconfirmed partial responses in a phase 1b study.
Frazier Life Sciences has gathered…
Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments for its 12th venture fund aimed at private early-stage biotechs.
AbbVie has reportedly added…
AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. The Big Pharma teamed up with Gilgamesh last year and, according to Bloomberg, is now in talks about buying the mental health biotech outright for
The FDA has missed the date for…
The FDA has missed the date for Coya Therapeutics’ investigational new drug application, citing a lack of resources and its current workload as reasons for the delay, according to a legal filing from the biotech.
Weeks after the biotech gave up on…
Weeks after the biotech gave up on a psoriasis trial of one drug that was hit with a partial clinical hold, Vyne's lead candidate has now failed a midstage vitiligo trial.
Cardiff Oncology has reported…
Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data it believes can support talks with the FDA about a registrational program. Investors responded by sending the biotech’s share
Madrigal Pharmaceuticals is paying…
Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its recently approved fatty liver disease med Rezdiffra.